Complete Genomics (GNOM) & Its Competitors Critical Review

Complete Genomics (NASDAQ: GNOM) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it weigh in compared to its peers? We will compare Complete Genomics to related businesses based on the strength of its analyst recommendations, dividends, earnings, institutional ownership, risk, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and target prices for Complete Genomics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Complete Genomics 0 0 0 0 N/A
Complete Genomics Competitors 90 441 836 13 2.56

As a group, “Medical Software & Technology Services” companies have a potential upside of 18.34%. Given Complete Genomics’ peers higher probable upside, analysts clearly believe Complete Genomics has less favorable growth aspects than its peers.

Profitability

This table compares Complete Genomics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Complete Genomics N/A N/A N/A
Complete Genomics Competitors -14.47% -7.27% 0.23%

Earnings and Valuation

This table compares Complete Genomics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Complete Genomics N/A N/A -1.34
Complete Genomics Competitors $413.57 million -$24.55 million 402.83

Complete Genomics’ peers have higher revenue, but lower earnings than Complete Genomics. Complete Genomics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

62.7% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 24.5% of shares of all “Medical Software & Technology Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Complete Genomics peers beat Complete Genomics on 6 of the 8 factors compared.

Complete Genomics Company Profile

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

What are top analysts saying about Complete Genomics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Complete Genomics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit